A
40.91
1.71 (4.36%)
| 前收盘价格 | 39.20 |
| 收盘价格 | 39.90 |
| 成交量 | 294,505 |
| 平均成交量 (3个月) | 694,651 |
| 市值 | 2,387,867,648 |
| 股市价格/股市净资产 (P/B) | 3.68 |
| 52周波幅 | |
| 利润日期 | 12 May 2025 - 16 May 2025 |
| 稀释每股收益 (EPS TTM) | -3.61 |
| 总债务/股东权益 (D/E MRQ) | 1.75% |
| 流动比率 (MRQ) | 15.82 |
| 营业现金流 (OCF TTM) | -188.02 M |
| 杠杆自由现金流 (LFCF TTM) | -120.81 M |
| 资产报酬率 (ROA TTM) | -19.65% |
| 股东权益报酬率 (ROE TTM) | -27.85% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Apogee Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
2.0
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.00 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 7.62% |
| 机构持股比例 | 137.71% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 116.00 (Guggenheim, 183.55%) | 购买 |
| 中 | 87.00 (112.66%) | |
| 低 | 60.00 (RBC Capital, 46.66%) | 购买 |
| 平均值 | 87.67 (114.30%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 39.49 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 25 Sep 2025 | 60.00 (46.66%) | 购买 | 37.52 |
| B of A Securities | 28 Aug 2025 | 87.00 (112.66%) | 购买 | 36.62 |
| Guggenheim | 02 Jul 2025 | 116.00 (183.55%) | 购买 | 44.32 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合